Indications in the market include Type 2 Diabetes at 5.0 to 20.0 USD Billion, Obesity at 3.0 to 12.0 USD Billion, and Cardiovascular Diseases at 2.77 to 10.0 USD Billion
Readers may view the current Sermorelin offer (official ReadyRx page) for additional details
Tesamorelin could offer broader metabolic health benefits
While medications like Ozempic, Wegovy, and Mounjaro have achieved global name-brand recognition, the real question isnt just whether GLP-1 works to help you lose weight (it does)
How these medications are showing promise in treating Alzheimers, multiple sclerosis, and other chronic conditions
Prior to several GLP-1s becoming popular obesity therapeutics, the class of drugs had been in use for many years in the treatment of type 2 diabetes